Sentinel lymph node biopsy (SLNB) has limited influence on adjuvant treatment decisions in women aged 65 years or older with clinical T2N0 hormone receptor-positive/HER2-negative breast cancer. Chemotherapy choices were primarily driven by genomic assays rather than nodal status, and most node-positive patients did not receive regional nodal irradiation. These results support a selective, individualized approach to axillary staging in this patient group.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
